Radiopeptide transmitted internal irradiation of non-iodophil thyroid cancer and conventionally untreatable medullary thyroid cancer using [90Y]-DOTA-D-Phe1-Tyr3-octreotide: a pilot study
作者： C. WALDHERR , T. SCHUMACHER , M. PLESS , A. CRAZZOLARA , H. R. MAECKE
DOI: 10.1097/00006231-200106000-00011
关键词:
摘要: Aim Differentiated thyroid carcinomas (DTC) and medullary (MTC) overexpress somatostatin receptor subtypes (sstr). The aim of this pilot study was to evaluate the tumour response targeted irradiation with radiolabelled analogue [90Y]-1,4,7
sci-hub.se 参考文章(24)
A. Otte, E. Jermann, M. Behe, M. Goetze, H. C. Bucher, H. W. Roser, A. Heppeler, J. Mueller-Brand, H. R. Maecke, DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. European Journal of Nuclear Medicine and Molecular Imaging. ,vol. 24, pp. 792- 795 ,(1997) , 10.1007/BF00879669
Anthony J. Coakley, Drug Therapy Alternatives in the Treatment of Thyroid Cancer Drugs. ,vol. 55, pp. 801- 812 ,(1998) , 10.2165/00003495-199855060-00007
Douglas B. Evans, Jason B. Fleming, Jeffrey E. Lee, Gilbert Cote, Robert F. Gagel, The surgical treatment of medullary thyroid carcinoma Seminars in Surgical Oncology. ,vol. 16, pp. 50- 63 ,(1999) , 10.1002/(SICI)1098-2388(199901/02)16:1<50::AID-SSU9>3.0.CO;2-6
Marta Cremonesi, Mahila Ferrari, Stefania Zoboli, Marco Chinol, Michael G. Stabin, Franco Orsi, Helmut R. Maecke, Eduard Jermann, Christopher Robertson, Maurizio Fiorenza, Giampiero Tosi, Giovanni Paganelli, Biokinetics and dosimetry in patients administered with 111In-DOTA-Tyr3-octreotide: Implications for internal radiotherapy with 90Y-DOTATOC European Journal of Nuclear Medicine and Molecular Imaging. ,vol. 26, pp. 877- 886 ,(1999) , 10.1007/S002590050462
Scott A. Hundahl, Irvin D. Fleming, Amy M. Fremgen, Herman R. Menck, A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 Cancer. ,vol. 83, pp. 2638- 2648 ,(1998) , 10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1
A. Otte, R. Herrmann, A. Heppeler, M. Behe, E. Jermann, P. Powell, H. R. Maecke, J. Muller, Yttrium-90 DOTATOC: first clinical results. European Journal of Nuclear Medicine and Molecular Imaging. ,vol. 26, pp. 1439- 1447 ,(1999) , 10.1007/S002590050476
A Heppeler, S Froidevaux, HR Mäcke, E Jermann, M Béhé, P Powell, M Hennig, None, Radiometal-Labelled Macrocyclic Chelator-Derivatised Somatostatin Analogue with Superb Tumour-Targeting Properties and Potential for Receptor-Mediated Internal Radiotherapy Chemistry - A European Journal. ,vol. 5, pp. 1974- 1981 ,(1999) , 10.1002/(SICI)1521-3765(19990702)5:7<1974::AID-CHEM1974>3.0.CO;2-X
Marion De Jong, Willem H. Bakker, Wout A. P. Breeman, Bert F. Bernard, Leo J. Hofland, Theo J. Visser, Ananth Srinivasan, Michelle Schmidt, Martin Béhé, Helmut R. Mäcke, Eric P. Krenning, Pre-clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy. International Journal of Cancer. ,vol. 75, pp. 406- 411 ,(1998) , 10.1002/(SICI)1097-0215(19980130)75:3<406::AID-IJC14>3.0.CO;2-6
M. DE JONG, B. F. BERNARD, E. DE BRUIN, A. VAN GAMEREN, W. H. BAKKER, T. J. VISSER, H. R. MÄCKE, E. P. KRENNING, Internalization of radiolabelled [DTPA0]octreotide and [DOTA0,Tyr3]octreotide: peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Nuclear Medicine Communications. ,vol. 19, pp. 283- 288 ,(1998) , 10.1097/00006231-199803000-00013
Melvin A. Block, Clinical characteristics distinguishing hereditary from sporadic medullary thyroid carcinoma. Treatment implications. Archives of Surgery. ,vol. 115, pp. 142- 148 ,(1980) , 10.1001/ARCHSURG.1980.01380020012004